Belenguer claims new biologic therapies are more effective in treating multiple sclerosis but have more side effects



[Valencià](/upo/rest/publicacion/idioma/ca?urlRedirect=https://www.uji.es/com/noticies/2012/7/2q/curs15-belenguer/&url=/com/noticies/2012/7/2q/curs15-belenguer/&urlRedirect=https://www.uji.es/com/noticies/2012/7/2q/curs15-belenguer/ "Cambiar idioma a català")
[Español](/upo/rest/publicacion/idioma/es?urlRedirect=https://www.uji.es/com/noticies/2012/7/2q/curs15-belenguer/&url=/com/noticies/2012/7/2q/curs15-belenguer/&urlRedirect=https://www.uji.es/com/noticies/2012/7/2q/curs15-belenguer/ "Cambiar idioma a español")
[English](#0)

Mobile menu

* [Profile](#0)
  + [Future students](/perfils/futurs/)
  + [UJI students](/perfils/estudiantat/uji/)
  + [PDI-PI](/perfils/pdipas/base/pdi/)
  + [PTGAS](/perfils/pdipas/base/pas/)
  + [AlumniSAUJI](/serveis/alumnisauji/)
  + [Companies and institutions](/perfils/empresa/)
* [Tools](#0)
  + [Virtual Classroom](https://aulavirtual.uji.es/)
  + [CAU](https://cau.uji.es/)
  + [Directory](//www.uji.es/institucional/contacta/)
  + [Gmail](http://gmail.uji.es/)
  + [Intranet (IGLU)](//www.uji.es/upo/rest/iglu/)
  + [Virtual Office](/seu/)
  + [Academic information (SIA)](http://sia.uji.es/)
  + [Others](//www.uji.es/serveis/scp/eines/)
* [Valencià](/upo/rest/publicacion/idioma/ca?urlRedirect=https://www.uji.es/com/noticies/2012/7/2q/curs15-belenguer/&url=/com/noticies/2012/7/2q/curs15-belenguer/&urlRedirect=https://www.uji.es/com/noticies/2012/7/2q/curs15-belenguer/ "Cambiar idioma a català")
  [Español](/upo/rest/publicacion/idioma/es?urlRedirect=https://www.uji.es/com/noticies/2012/7/2q/curs15-belenguer/&url=/com/noticies/2012/7/2q/curs15-belenguer/&urlRedirect=https://www.uji.es/com/noticies/2012/7/2q/curs15-belenguer/ "Cambiar idioma a español")
  [English](#0)

[# Universitat Jaume I](/)

* [# Universitat Jaume I](/)
* [Profile](#0)
  + [Future students](/perfils/futurs/)
  + [UJI students](/perfils/estudiantat/uji/)
  + [PDI-PI](/perfils/pdipas/base/pdi/)
  + [PTGAS](/perfils/pdipas/base/pas/)
  + [AlumniSAUJI](/serveis/alumnisauji/)
  + [Companies and institutions](/perfils/empresa/)
* [Tools](#0)
  + [Virtual Classroom](https://aulavirtual.uji.es/)
  + [CAU](https://cau.uji.es/)
  + [Directory](//www.uji.es/institucional/contacta/)
  + [Gmail](http://gmail.uji.es/)
  + [Intranet (IGLU)](//www.uji.es/upo/rest/iglu/)
  + [Virtual Office](/seu/)
  + [Academic information (SIA)](http://sia.uji.es/)
  + [Others](//www.uji.es/serveis/scp/eines/)
* [Studies](/mapa/estudis/)
  + [Studies](/mapa/estudis/)
  + [Bachelor’s degrees](/estudis/)
  + [University master’s degrees](/estudis/?p_estudio=m)
  + [Doctoral studies](/estudis/oferta/doctorat/)
  + [Lifelong learning](/estudis/base/formacio-permanent/)
* [Research and innovation](/investigacio/)
  + [Research and innovation](/investigacio/)
  + [Research portal](/investigacio/)
  + [Innovation](/innovacio/)
  + [Doctoral studies](/centres/escola-doctorat/)
  + [HRS4R](/investigacio/hrs4r/)
* [International](/internacional/)
  + [International](/internacional/)
  + [International Students](/internacional/base/estudiantat/estudiantado-internacional/)
  + [Exchange Programmes](/serveis/ori/base/programes-intercanvi/)
  + [Study Abroad](/internacional/base/study-abroad/)
* [UJI](/mapa/uji/)
  + [UJI](/mapa/uji/)
  + [Get to know the UJI](/mapa/uji/coneix-uji/)
  + [Structure and organisation](/institucional/estructura/)
  + [Strategy and quality](/institucional/estrategia/)
  + [Transparency](/transparencia/)
  + [Public integrity](/transparencia/liniaetica/)
  + [News](/actualitat/)
  + [Contact the UJI](/institucional/contacta/)
* [University life](/mapa/vida-universitaria/)
  + [University life](/mapa/serveis/)
  + [Library](/serveis/cd/)
  + [Campus](/mapa/uji/coneix-uji/campus/)
  + [Culture](/cultura/)
  + [Sports](/esports/)
  + [InfoCampus](/serveis/infocampus/)

[UJI](/)
[News](/com/sumari/noticies/)

## Belenguer claims new biologic therapies are more effective in treating multiple sclerosis but have more side effects

04/09/2016 |
SCP

Compartir

Compartir

×

Linkedin

BlueSky

Facebook

Mastodon

Whatsapp

Gmail

Imprimir

Image resource curs15-belenguer CESTIU15\_Antonio\_Belenguer\_20120718\_DLL0015
Current slide

Image resource curs15-belenguer CESTIU15\_Antonio\_Belenguer\_20120718\_DLL0014

* [![ curs15-belenguer CESTIU15_Antonio_Belenguer_20120718_DLL0015](/com/noticies/2012/7/2q/curs15-belenguer/CESTIU15_Antonio_Belenguer_20120718_DLL0015.jpg)](#)
* [![ curs15-belenguer CESTIU15_Antonio_Belenguer_20120718_DLL0014](/com/noticies/2012/7/2q/curs15-belenguer/CESTIU15_Antonio_Belenguer_20120718_DLL0014.jpg)](#)

Antonio Belenguer, neurólogo of the General Hospital of Castellón, has tackled today the treatments of the Multiple Sclerosis (EM) in the conference that has offered in the course of summer of the Universitat Jaume I “multiple Sclerosis: how has to tackle and act from an interdisciplinary perspective”. Belenguer Has stood out the importance of the precocious treatment in the EM since it diminishes of important form the probability to have a second shoot of the illness.

The neurólogo has initiated his intervention explaining that “the existent therapies up to now were only partially effective, by what needed something more: effective drugs, safe (without important secondary effects), selective (that they act only on the causes of the illness), to be possible oral (not to alter the quality of life of the patient) and that if have secondary effects are reversible”. Belenguer Has explained that looking for this new generation of medicines have realised different studies that have concluded with the exit to the market of new drugs. The specialist, that has centred his intervention in the drugs that can modify the course of the illness, has analysed, more in detail, two of the new biological therapies: the oral agents (Fingolimod, Dimetil Fumarato, Laquinimod and Teriflunomida); and the antibodies monoclonales (Natalizumab, Daclizumab, Alemtuzumab and Ocrelizumab), “much more effective that the previous but with more secondary effects”.

Like conclusion, Antonio Belenguer has explained that exist several effective biological molecules with clear profits: mejoría in control of the illness, greater adherencia to the drug and an a lot greater efficiency; but also with some risks by the secondary effects and the elevation of the pharmaceutical cost. Likewise, it has indicated the big pending challenges in the treatment of the illness: find treatment for the most progressive phases and the phase neurodegenerativa of the EM, treatments neuroreparadores, and biological markers of activity “so that the patients do not have to carry treatment for life and only have to treat when there is inflammation to avoid secondary effects and infections”.

Photographies: [http://www.uji.es/noticies/foto/num&go\_to=29415697.](http://www.uji.es/noticies/foto/num&id_a=29415697)

Information provided by:
[Communication and Publications Service](/serveis/scp/)

News

[Agenda](/com/sumari/agenda/)
[Government meeting agenda](/transparencia/uji/organs/collegiats/agenda/)
[News](/com/sumari/noticies/)
[Photo news](/com/fotonoticies/actual/)
[Government bodies news](/com/acords/)
[Vox UJI](/com/voxuji/)
[Vox UJI Ràdio](http://www.radio.uji.es/)
[Video server](http://www.svideo.uji.es)
[CienciaUJI](/com/investigacio/cienciauji/)
[Ciència UJI TV](/com/investigacio/arxiu/ciencia-uji-tv/)



Useful links

[University card](http://www.carnet.uji.es/)

[Multimedia catalogue](http://jecom.uji.es/)

[University press](/serveis/scp/publ/)

[Web map](//www.uji.es/mapa/)

[Educational model](//www.uji.es/institucional/estrategia/modeleducatiu/)

[Language Observatory](/serveis/ol/)

[Open Knowledge Portal](/serveis/cd/bib/pco/)

[UJI shop](http://www.tenda.uji.es/)

[Security and privacy center](https://www.uji.es/organs/ouag/sg/docs/politiques/gen/)
|
[Website legal notice](https://www.uji.es/comu/avislegal/avislegalicondicions/)
|
[Accessibility policy](https://www.uji.es/serveis/ura/base/accessibilitat/)

Information and queries:
[UJI suggestion box](/comu/forms/bustia)

Universitat Jaume I CIF: Q-6250003-H Av. Vicent Sos Baynat, s/n 12071
Castellón de la Plana,
España

Tel.: +34 964 72 80 00